Omega Diagnostics Group PLC Logo

Omega Diagnostics Group PLC

ODX.L

(1.0)
Stock Price

2,08 GBp

-39.07% ROA

-35.47% ROE

-1.25x PER

Market Cap.

4.943.848,00 GBp

0.74% DER

0% Yield

-51.15% NPM

Omega Diagnostics Group PLC Stock Analysis

Omega Diagnostics Group PLC Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Omega Diagnostics Group PLC Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (1%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

With a remarkably low PBV ratio (0.48x), the stock offers substantial upside potential at a bargain price.

3 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

4 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

5 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

7 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

8 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

9 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

10 ROE

Negative ROE (-35.47%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

11 ROA

The stock's ROA (-39.07%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

Omega Diagnostics Group PLC Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Omega Diagnostics Group PLC Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

Omega Diagnostics Group PLC Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Omega Diagnostics Group PLC Revenue
Year Revenue Growth
2004 0
2005 0 0%
2006 0 0%
2007 3.492.000 100%
2008 5.438.000 35.79%
2009 6.199.000 12.28%
2010 7.902.000 21.55%
2011 11.124.000 28.96%
2012 11.262.898 1.23%
2013 11.593.870 2.85%
2014 12.105.319 4.22%
2015 12.743.896 5.01%
2016 14.246.930 10.55%
2017 13.552.726 -5.12%
2018 8.756.756 -54.77%
2019 9.818.662 10.82%
2020 9.818.662 0%
2021 8.539.000 -14.99%
2022 7.546.000 -13.16%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Omega Diagnostics Group PLC Research and Development Expenses
Year Research and Development Expenses Growth
2004 0
2005 0 0%
2006 0 0%
2007 137.000 100%
2008 226.000 39.38%
2009 210.000 -7.62%
2010 250.000 16%
2011 487.000 48.67%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Omega Diagnostics Group PLC General and Administrative Expenses
Year General and Administrative Expenses Growth
2004 79.000
2005 56.000 -41.07%
2006 0 0%
2007 1.600.000 100%
2008 1.560.000 -2.56%
2009 1.708.000 8.67%
2010 2.028.000 15.78%
2011 -2.420.000 183.8%
2012 4.448.646 154.4%
2013 4.741.186 6.17%
2014 5.278.903 10.19%
2015 5.917.453 10.79%
2016 6.434.227 8.03%
2017 6.923.715 7.07%
2018 4.695.486 -47.45%
2019 5.374.849 12.64%
2020 5.374.849 0%
2021 4.438.000 -21.11%
2022 4.755.000 6.67%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Omega Diagnostics Group PLC EBITDA
Year EBITDA Growth
2004 -73.000
2005 -49.000 -48.98%
2006 0 0%
2007 353.000 100%
2008 648.000 45.52%
2009 468.000 -38.46%
2010 466.000 -0.43%
2011 1.336.000 65.12%
2012 983.463 -35.85%
2013 1.251.877 21.44%
2014 1.418.525 11.75%
2015 1.317.725 -7.65%
2016 1.293.973 -1.84%
2017 -365.009 454.5%
2018 201.858 280.82%
2019 838.895 75.94%
2020 -6.893.637 112.17%
2021 697.000 1089.04%
2022 -2.124.000 132.82%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Omega Diagnostics Group PLC Gross Profit
Year Gross Profit Growth
2004 0
2005 0 0%
2006 0 0%
2007 1.898.000 100%
2008 3.344.000 43.24%
2009 3.616.000 7.52%
2010 4.706.000 23.16%
2011 7.004.000 32.81%
2012 7.052.993 0.69%
2013 7.370.870 4.31%
2014 7.673.648 3.95%
2015 8.135.513 5.68%
2016 9.221.554 11.78%
2017 8.192.815 -12.56%
2018 5.632.329 -45.46%
2019 6.293.973 10.51%
2020 6.293.973 0%
2021 5.102.000 -23.36%
2022 3.545.000 -43.92%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Omega Diagnostics Group PLC Net Profit
Year Net Profit Growth
2004 -73.000
2005 -85.000 14.12%
2006 0 0%
2007 238.000 100%
2008 221.000 -7.69%
2009 187.000 -18.18%
2010 31.000 -503.23%
2011 527.000 94.12%
2012 582.266 9.49%
2013 692.851 15.96%
2014 739.046 6.25%
2015 571.912 -29.22%
2016 713.261 19.82%
2017 -7.269.597 109.81%
2018 974.253 846.17%
2019 -6.828.312 114.27%
2020 -6.828.312 0%
2021 -1.409.000 -384.62%
2022 -3.860.000 63.5%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Omega Diagnostics Group PLC Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2004 0
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Omega Diagnostics Group PLC Free Cashflow
Year Free Cashflow Growth
2004 -63.000
2005 -78.000 19.23%
2007 153.000 150.98%
2008 573.000 73.3%
2009 80.000 -616.25%
2010 -443.000 118.06%
2011 -550.000 19.45%
2012 -479.056 -14.81%
2013 -690.706 30.64%
2014 -847.818 18.53%
2015 -585.512 -44.8%
2016 -649.013 9.78%
2017 -4.107.537 84.2%
2018 -2.325.657 -76.62%
2019 -1.606.236 -44.79%
2020 -401.559 -300%
2021 -4.707.000 91.47%
2022 -3.305.000 -42.42%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Omega Diagnostics Group PLC Operating Cashflow
Year Operating Cashflow Growth
2004 -63.000
2005 -78.000 19.23%
2007 311.000 125.08%
2008 600.000 48.17%
2009 170.000 -252.94%
2010 322.000 47.2%
2011 673.000 52.15%
2012 1.014.953 33.69%
2013 1.669.107 39.19%
2014 1.247.893 -33.75%
2015 1.453.676 14.16%
2016 2.011.324 27.73%
2017 -828.497 342.77%
2018 368.819 324.64%
2019 547.607 32.65%
2020 136.902 -300%
2021 -3.229.000 104.24%
2022 -3.152.000 -2.44%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Omega Diagnostics Group PLC Capital Expenditure
Year Capital Expenditure Growth
2004 0
2005 0 0%
2007 158.000 100%
2008 27.000 -485.19%
2009 90.000 70%
2010 765.000 88.24%
2011 1.223.000 37.45%
2012 1.494.009 18.14%
2013 2.359.813 36.69%
2014 2.095.711 -12.6%
2015 2.039.188 -2.77%
2016 2.660.337 23.35%
2017 3.279.040 18.87%
2018 2.694.476 -21.69%
2019 2.153.843 -25.1%
2020 538.461 -300%
2021 1.478.000 63.57%
2022 153.000 -866.01%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Omega Diagnostics Group PLC Equity
Year Equity Growth
2004 206.000
2005 122.000 -68.85%
2007 3.460.000 96.47%
2008 4.365.000 20.73%
2009 5.650.000 22.74%
2010 12.966.000 56.42%
2011 13.324.000 2.69%
2012 13.962.478 4.57%
2013 18.458.569 24.36%
2014 18.813.150 1.88%
2015 20.187.177 6.81%
2016 21.457.936 5.92%
2017 17.122.156 -25.32%
2018 18.190.642 5.87%
2019 13.608.325 -33.67%
2020 23.674.289 42.52%
2021 11.816.000 -100.36%
2022 9.951.000 -18.74%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Omega Diagnostics Group PLC Assets
Year Assets Growth
2004 222.000
2005 152.000 -46.05%
2007 8.057.000 98.11%
2008 8.261.000 2.47%
2009 9.150.000 9.72%
2010 17.402.000 47.42%
2011 16.710.000 -4.14%
2012 17.608.143 5.1%
2013 21.990.771 19.93%
2014 22.638.816 2.86%
2015 23.777.062 4.79%
2016 25.758.655 7.69%
2017 22.901.553 -12.48%
2018 23.475.223 2.44%
2019 18.835.798 -24.63%
2020 30.989.455 39.22%
2021 17.835.000 -73.76%
2022 14.405.000 -23.81%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Omega Diagnostics Group PLC Liabilities
Year Liabilities Growth
2004 16.000
2005 30.000 46.67%
2007 4.597.000 99.35%
2008 3.896.000 -17.99%
2009 3.500.000 -11.31%
2010 4.436.000 21.1%
2011 3.386.000 -31.01%
2012 3.645.665 7.12%
2013 3.532.202 -3.21%
2014 3.825.666 7.67%
2015 3.589.885 -6.57%
2016 4.300.719 16.53%
2017 5.779.397 25.59%
2018 5.284.581 -9.36%
2019 5.227.473 -1.09%
2020 7.315.166 28.54%
2021 6.019.000 -21.53%
2022 4.454.000 -35.14%

Omega Diagnostics Group PLC Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.03
Net Income per Share
-0.02
Price to Earning Ratio
-1.25x
Price To Sales Ratio
0.66x
POCF Ratio
-1.53
PFCF Ratio
-1.5
Price to Book Ratio
0.48
EV to Sales
-0.01
EV Over EBITDA
0.05
EV to Operating CashFlow
0.03
EV to FreeCashFlow
0.03
Earnings Yield
-0.8
FreeCashFlow Yield
-0.67
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.13
Graham NetNet
0

Income Statement Metrics

Net Income per Share
-0.02
Income Quality
0.82
ROE
-0.35
Return On Assets
-0.27
Return On Capital Employed
-0.22
Net Income per EBT
1.19
EBT Per Ebit
1.2
Ebit per Revenue
-0.36
Effective Tax Rate
0.02

Margins

Sales, General, & Administrative to Revenue
0.63
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.47
Operating Profit Margin
-0.36
Pretax Profit Margin
-0.43
Net Profit Margin
-0.51

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.01
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
0.05
Capex to Revenue
-0.02
Capex to Depreciation
-0.26
Return on Invested Capital
-0.26
Return on Tangible Assets
-0.39
Days Sales Outstanding
0
Days Payables Outstanding
139.12
Days of Inventory on Hand
70.88
Receivables Turnover
0
Payables Turnover
2.62
Inventory Turnover
5.15
Capex per Share
-0

Balance Sheet

Cash per Share
0,02
Book Value per Share
0,04
Tangible Book Value per Share
0.02
Shareholders Equity per Share
0.04
Interest Debt per Share
0
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
2.37
Current Ratio
4.29
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0.01
Working Capital
0,01 Bil.
Intangibles to Total Assets
0.31
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
935500
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Omega Diagnostics Group PLC Dividends
Year Dividends Growth

Omega Diagnostics Group PLC Profile

About Omega Diagnostics Group PLC

Omega Diagnostics Group PLC, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products in the United Kingdom, rest of Europe, North America, South/Central America, India, other Asian countries and the Far East, Africa, and the Middle East. The company operates through two segments, Health and Nutrition, and Global Health and Other. The Health and Nutrition segment engages in the research, development, and production of kits to aid the detection of immune reactions to food under the Foodprint name. This segment also provides clinical analysis to the general public, clinics, and health professionals, as well as supplies Food Detective, a consumer food test. The Global Health and Other segment engages in the research, development, production, and marketing of kits that are used in the diagnosis of infectious diseases. This segment offers VISITECT CD4, an advanced disease rapid test, which is used to treat patients with HIV; and AbC-19, a COVID-19 antibody testing kit, as well as COVID-19 antigen and antibody testing solutions. The company offers its products to hospitals, clinics, laboratories, and healthcare practitioners through distributors in approximately 75 countries worldwide. Omega Diagnostics Group PLC was founded in 1987 and is headquartered in Alva, the United Kingdom.

CEO
Mr. Jagdeep Grewal B.Sc., M.B
Employee
91
Address
Omega House
Alva, FK12 5DQ

Omega Diagnostics Group PLC Executives & BODs

Omega Diagnostics Group PLC Executives & BODs
# Name Age
1 Mr. Prashant Maniar
Managing Director of Omega Dx Asia Pvt Limited
70
2 Mr. Iain Logan
Group Financial Controller
70
3 Mr. Jagdeep Grewal B.Sc., M.B.A., M.Sc.
Chief Executive Officer & Executive Director
70
4 Mr. Christopher Paul Lea A.C.A., B.Sc.
Chief Financial Officer, Company Sec. & Director
70
5 Mr. Iain Alexander James Logan
Group Financial Controller
70
6 Mr. Andrew William Shepherd
Global Ambassador - Life Pres
70

Omega Diagnostics Group PLC Competitors

Avacta Group Plc Logo
Avacta Group Plc

AVCT.L

(0.0)
Novacyt S.A. Logo
Novacyt S.A.

NCYT.L

(1.0)
genedrive plc Logo
genedrive plc

GDR.L

(0.8)
Synairgen plc Logo
Synairgen plc

SNG.L

(1.0)